COMPANY
Gate Bioscience
Raises and deals from press releases
- Deal Deal · up to $870M total · announced Oct 5, 2026 Company release ↗
Source quote
- Oct 5, 2026 · Company release ↗
“The total potential value of the agreement could exceed $870 million, contingent on the achievement of milestones.”
- Oct 5, 2026 · Company release ↗
- Raise Series B · $65M · announced Nov 13, 2025 Company release ↗
Source quote
- Nov 13, 2025 · Company release ↗
“Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic”
- Nov 13, 2025 · Company release ↗
- Deal Lilly deal · amount not disclosed · announced Jul 24, 2025 Company release ↗
Source quote
- Jul 24, 2025 · Company release ↗
“Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company (“Lilly”) to discover”
- Jul 24, 2025 · Company release ↗
Timeline
Funding
- Private equity round — Series B: $65M (total, as published), announced Nov 13, 2025. Source: company release on GlobeNewswire. source ↗
Raises and investors new
- InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗